Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 8/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 8/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811933 | 0.88 | CACNA1G (0.41) | CACNA1GCACNA1HCACNA1IALDH1A1P2RX7 | |
| SCHEMBL2812136 | 0.87 | POLB (0.41) | CACNA1GCACNA1HCACNA1IP2RX7MC4R | |
| SCHEMBL2814288 | 0.87 | KMT2A (0.39) | CACNA1GCACNA1HCACNA1IALDH1A1MAPT | |
| SCHEMBL2815946 | 0.87 | MC4R (0.44) | CACNA1GCACNA1HCACNA1IKDM4EMC4R | |
| SCHEMBL2812037 | 0.86 | KCNH2 (0.39) | CACNA1GCACNA1HCACNA1IP2RX7KMT2A | |
| SCHEMBL538333 | 0.85 | ENPP2 (0.38) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL538003 | 0.84 | KDM1A (0.40) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2812146 | 0.84 | ALDH1A1 (0.40) | CACNA1GCACNA1HCACNA1IKDM4EALDH1A1 | |
| SCHEMBL537588 | 0.83 | ALDH1A1 (0.45) | KDM4EALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL2811169 | 0.82 | HPGD (0.38) | CACNA1GCACNA1HCACNA1IKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414359-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | CACNA1G 4588/4885CACNA1H 4714/4885CACNA1I 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.